{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T08:04:34Z","timestamp":1780473874138,"version":"3.54.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100013983","name":"Wills Eye Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013983","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Retina"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.oret.2026.02.009","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T08:06:43Z","timestamp":1770710803000},"page":"615-624","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Eyes Achieving Absence of Diabetic Macular Edema and Very Good Vision"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-6062-4894","authenticated-orcid":false,"given":"Roselind","family":"Ni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5435-7369","authenticated-orcid":false,"given":"Bita","family":"Momenaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5818-9083","authenticated-orcid":false,"given":"Raziyeh","family":"Mahmoudzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8654-2876","authenticated-orcid":false,"given":"Mirataollah","family":"Salabati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah J.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell S.","family":"Fineman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6847-7169","authenticated-orcid":false,"given":"Yoshihiro","family":"Yonekawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James F.","family":"Vander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2761-4219","authenticated-orcid":false,"given":"Jason","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.oret.2026.02.009_bib1","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.2337\/dci23-0048","article-title":"Executive summary: guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus","volume":"46","author":"Sacks","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.oret.2026.02.009_bib2","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/S0140-6736(24)02317-1","article-title":"Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants","volume":"404","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.oret.2026.02.009_bib3","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.survophthal.2022.01.009","article-title":"Prevalence of diabetic macular edema based on optical coherence tomography in people with diabetes: a systematic review and meta-analysis","volume":"67","author":"Im","year":"2022","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.oret.2026.02.009_bib5","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1001\/jamaophthalmol.2022.6142","article-title":"DRCR Retina Network. Cost-effectiveness of aflibercept monotherapy vs bevacizumab first followed by aflibercept if needed for diabetic macular edema","volume":"141","author":"Hutton","year":"2023","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oret.2026.02.009_bib7","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1001\/jamaophthalmol.2016.1669","article-title":"Cost-effectiveness of aflibercept, bevacizumab, and ranibizumab for diabetic macular edema treatment: analysis from the diabetic retinopathy clinical research network comparative effectiveness trial","volume":"134","author":"Ross","year":"2016","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oret.2026.02.009_bib8","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMoa1414264","article-title":"Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema","volume":"372","author":"Wells","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.oret.2026.02.009_bib9","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1056\/NEJMoa2204225","article-title":"Aflibercept monotherapy or bevacizumab first for diabetic macular edema","volume":"387","author":"Jhaveri","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.oret.2026.02.009_bib10","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.ophtha.2024.01.037","article-title":"Risk factors for meeting criteria for switching from bevacizumab to aflibercept when treating eyes with diabetic macular edema and visual acuity of <20\/40","volume":"131","author":"Jhaveri","year":"2024","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2026.02.009_bib11","doi-asserted-by":"crossref","first-page":"8154","DOI":"10.1167\/iovs.12-10290","article-title":"Retinal thickness in people with diabetes and minimal or no diabetic retinopathy: Heidelberg Spectralis optical coherence tomography","volume":"53","author":"Chalam","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.oret.2026.02.009_bib12","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1001\/jamaophthalmol.2019.6035","article-title":"Assessment of the DRCR retina network approach to management with initial observation for eyes with center-involved diabetic macular edema and good visual acuity: a secondary analysis of a randomized clinical trial","volume":"138","author":"Glassman","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oret.2026.02.009_bib13","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/IAE.0000000000002852","article-title":"Association of serum vasogenic and proinflammatory factors with clinical response to anti-vascular endothelial growth factor for diabetic macular edema","volume":"41","author":"Brito","year":"2021","journal-title":"Retina (Philadelphia, Pa)"},{"key":"10.1016\/j.oret.2026.02.009_bib14","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.4103\/ijo.IJO_3109_20","article-title":"Significance of monitoring vascular endothelial growth factor, monocyte chemoattractant protein-1 and Interleukin-8 in diabetic macular edema towards early identification of nonresponders to ranibizumab therapy","volume":"69","author":"Xavier","year":"2021","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.oret.2026.02.009_bib15","doi-asserted-by":"crossref","first-page":"7428","DOI":"10.1038\/s41598-023-34673-z","article-title":"Efficacy and safety profile of intravitreal dexamethasone implant versus antivascular endothelial growth factor treatment in diabetic macular edema: a systematic review and meta-analysis","volume":"13","author":"Chi","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.oret.2026.02.009_bib16","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1136\/bjo-2023-324394","article-title":"Conversion to faricimab after prior anti-vascular endothelial growth factor therapy for persistent diabetic macular oedema","volume":"108","author":"Durrani","year":"2024","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.oret.2026.02.009_bib17","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1007\/s00417-025-06878-7","article-title":"Switching to faricimab after prior anti-vascular endothelial growth factor therapy for persistent diabetic macular edema: a systematic review and meta-analysis","volume":"263","author":"Tahmasebi","year":"2025","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.oret.2026.02.009_bib18","doi-asserted-by":"crossref","first-page":"6241","DOI":"10.1167\/iovs.17-22380","article-title":"Retinal reflectivity measurement for cone impairment estimation and visual assessment after diabetic macular edema resolution (RECOVER-DME)","volume":"58","author":"Guyon","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.oret.2026.02.009_bib19","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1167\/iovs.14-15503","article-title":"Correlation between ganglion cell layer thinning and poor visual function after resolution of diabetic macular edema","volume":"56","author":"Bonnin","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.oret.2026.02.009_bib20","doi-asserted-by":"crossref","DOI":"10.1038\/srep39161","article-title":"Restoration of foveal photoreceptors after intravitreal ranibizumab injections for diabetic macular edema","volume":"6","author":"Mori","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.oret.2026.02.009_bib21","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/s41433-019-0522-z","article-title":"Relationship between duration and extent of oedema and visual acuity outcome with ranibizumab in diabetic macular oedema: a post hoc analysis of Protocol I data","volume":"34","author":"Sadda","year":"2020","journal-title":"Eye"},{"key":"10.1016\/j.oret.2026.02.009_bib22","doi-asserted-by":"crossref","first-page":"4488","DOI":"10.1038\/s41598-021-83811-y","article-title":"Outcomes of a 2-year treat-and-extend regimen with aflibercept for diabetic macular edema","volume":"11","author":"Hirano","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.oret.2026.02.009_bib23","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000006406","article-title":"Two year result of intravitreal bevacizumab for diabetic macular edema using treat and extend protocol","volume":"96","author":"Sugimoto","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.oret.2026.02.009_bib24","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/S0140-6736(23)02577-1","article-title":"Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2\/3 trial","volume":"403","author":"Brown","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.oret.2026.02.009_bib25","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.2337\/dc22-2527","article-title":"The broader economic value of treatment for diabetic macular edema","volume":"46","author":"Mulligan","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.oret.2026.02.009_bib26","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1097\/IAE.0000000000004096","article-title":"Anti-vascular endothelial growth factor treatment in diabetic macular edema: results from a large single-center cohort with bevacizumab as first-line therapy","volume":"44","author":"Zur","year":"2024","journal-title":"Retina (Philadelphia, Pa)"},{"key":"10.1016\/j.oret.2026.02.009_bib27","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1038\/s41433-024-02998-2","article-title":"Real-world effects of anti-vascular endothelial growth factor injection frequency on visual outcomes in patients with diabetic macular oedema","volume":"38","author":"Payne","year":"2024","journal-title":"Eye"}],"container-title":["Ophthalmology Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653026000540?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653026000540?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:35:30Z","timestamp":1780472130000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468653026000540"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2468653026000540"],"URL":"https:\/\/doi.org\/10.1016\/j.oret.2026.02.009","relation":{},"ISSN":["2468-6530"],"issn-type":[{"value":"2468-6530","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Eyes Achieving Absence of Diabetic Macular Edema and Very Good Vision","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Retina","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oret.2026.02.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Academy of Ophthalmology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}